2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient risk
2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCost-Benefit AnalysisFemaleGene Expression ProfilingHumansNeoplasm StagingConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancer
2017
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsConnecticutFemaleGene Expression ProfilingGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHumansLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPatient Outcome AssessmentPopulation SurveillanceRegistriesRetrospective StudiesSocioeconomic FactorsYoung AdultConceptsPopulation-based studyOncotype DXODX testingBreast cancerHispanic womenHormone receptor-positive breast cancerReceptor-positive breast cancerRetrospective population-based studyWhite womenRacial disparitiesGEP test resultsBreast cancer careBreast cancer outcomesStudy inclusion criteriaGene expression profiling testsMore white womenClinical characteristicsTest receiptCancer outcomesCancer careInclusion criteriaLogistic analysisEthnic disparitiesStatewide populationWomen
2015
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal Of Clinical Oncology 2015, 33: 4267-4276. PMID: 26598753, DOI: 10.1200/jco.2015.63.7801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsianBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantComorbidityDatabases, FactualFemaleHispanic or LatinoHumansInsurance CoverageInsurance, HealthMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsPathologic complete responseNational Cancer Data BaseNeoadjuvant chemotherapyBreast cancerEstrogen receptorWhite womenPositive tumorsAsian womenHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Timing of chemotherapyClinical T stageGrowth factor receptor 2Triple-negative tumorsPatient's zip codeHigh-grade tumorsRacial differencesZip codesFactor receptor 2Chemotherapy useComorbidity indexComplete responseT stageGrade tumors
2014
Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care
Wang SY, Wang R, Yu JB, Ma X, Xu X, Kim SP, Soulos PR, Saraf A, Gross CP. Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. Medical Care 2014, 52: 680-687. PMID: 25023913, PMCID: PMC4129645, DOI: 10.1097/mlr.0000000000000158.Peer-Reviewed Original ResearchConceptsAncillary proceduresPatient characteristicsTreatment modalitiesTreatment intensityEnd Results-Medicare databaseProstate cancer careSpecific treatment modalitiesContribution of patientHospital referral regionsInitial treatmentCancer careInitial episodeNoncancer controlsProstate cancerQuintile 5Referral regionsSubstantial geographic variationCare costsMedicare expendituresCostly modalityTreatment factorsMean expenditureLowest expenditure quintileSurgeryModalitiesExamining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2013
The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer
Wang SY, Kuntz KM, Tuttle TM, Jacobs DR, Kane RL, Virnig BA. The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer. Breast Cancer Research And Treatment 2013, 138: 137-147. PMID: 23354364, DOI: 10.1007/s10549-013-2420-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBreast NeoplasmsFemaleHumansMagnetic Resonance ImagingNeoplasm StagingOdds RatioSEER ProgramConceptsEarly-stage breast cancerStage breast cancerMultiple surgeriesPreoperative breast MRIBreast cancerAdditional surgeryBreast surgeryPreoperative breast magnetic resonance imagingEnd Results-Medicare databaseBreast MRIInitial treatment episodeMore additional surgeriesPhysician-level predictorsBreast magnetic resonance imagingMagnetic resonance imaging (MRI) utilizationInitial treatment periodMultilevel logistic regression modelsMedian odds ratioMagnetic resonance imagingLogistic regression modelsPrimary surgeryTumor characteristicsMRI evaluationPartial mastectomyTreatment episodes
2011
Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis
Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Research And Treatment 2011, 127: 1-14. PMID: 21327465, DOI: 10.1007/s10549-011-1387-4.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceHER2/neu receptorTumor characteristicsLocal recurrenceDuctal carcinomaTumor sizeTumor gradeLow-risk DCIS patientsNeu receptorManagement of DCISBreast tumor recurrenceHigh-quality evidenceCourse of treatmentDCIS patientsAggressive treatmentPrognostic factorsSurgical marginsTumor recurrenceSubgroup analysisObservational studyMethod of detectionEligible articlesSystematic reviewRecurrenceDCIS